21875-67-2

Usage

Uses

Used in Pharmaceutical Industry:
7-CHLORO-N-METHYLQUINOLIN-4-AMINE is used as an intermediate in the synthesis of pharmaceuticals for its potential antitumor and antibacterial properties. It is particularly valuable in the development of new drugs targeting cancer and bacterial infections.
Used in Tuberculosis Treatment:
In the medical field, 7-CHLORO-N-METHYLQUINOLIN-4-AMINE is explored as a potential therapeutic agent for the treatment of tuberculosis, given its ability to target the causative agent of the disease and contribute to the development of effective treatment strategies.
Used in Organic Electronics:
7-CHLORO-N-METHYLQUINOLIN-4-AMINE is utilized in the field of organic electronics as a component with unique electronic properties. Its application in this industry is driven by the need for innovative materials that can enhance the performance of electronic devices and contribute to the advancement of technology.

InChI:InChI=1/C10H9ClN2/c1-12-9-4-5-13-10-6-7(11)2-3-8(9)10/h2-6H,1H3,(H,12,13)

Upstream product

• 86-98-6 4,7-dichloroquinoline 
• 74-89-5 methylamine 

Relevant academic research and scientific papers

QUINONE REDUCTASE 2 INHIBITORS FOR USE AS NEUROPROTECTIVE AGENTS

Provided herein according to some embodiments is a method of treating acute neural injury in a subject in need thereof, comprising administering to the subject a compound of Formula I or Formula II. Also provided is a method of treating vascular dementia in a subject in need thereof, comprising administering to the subject a compound of Formula I or Formula II. Further provided is a method of treating CNS lupus in a subject in need thereof, comprising administering to the subject a compound of Formula I or Formula II.

QUINONE REDUCTASE 2 INHIBITOR COMPOUNDS AND USES THEREOF

Provided herein according to some embodiments is a compound of Formula (I): [Formula], or a pharmaceutically acceptable salt or prodrug thereof. Compositions comprising the compound, and uses thereof for inhibiting the activity of quinone reductase-2, as well as in methods of treatment, are also provided.

Structure-activity relationships for ferriprotoporphyrin IX association and β-hematin inhibition by 4-aminoquinolines using experimental and ab initio methods

In order to probe structure-activity relationships of association with ferriprotoporphyrin IX (log K) and inhibition of β-hematin formation, a series of 4-aminoquinolines with varying substituents at the 7-position (X) have been synthesized. These have been further elaborated by introduction of two different R groups on the 4-amino nitrogen atom in the form of methyl (R = Me) and ethylamine (R = EtNH2) side chains. Data for a previously investigated series containing an N,N-diethyl-ethylamine side chain were also compared with the findings of this study. Experimentally, log K values for the simple 4-aminoquinoline series (R = H) were found to correlate with the hydrophobicity constant (π) of the group X. The log K values for the series with R = Me and EtNH2 were found to correlate with those of the series with R = H. The log of the 50% β-hematin inhibitory activity (log BHIA50) was found to correlate with log K and either meta (σm) or para (σp) Hammett constants for the series with R = Me and EtNH2, but not the simple series with R = H. To further improve predictability, correlations with ab initio electrostatic parameters, namely Mulliken and CHelpG charges were investigated. The best correlations were found with CHelpG charges which indicated that log K values can be predicted from the charges on atom H-8 and the group X in the quinolinium species computed in vacuum, while log BHIA50 values can be predicted from the CHelpG charges on C-7, C-8 and N-1 for the neutral species in vacuum. These correlations indicate that association and inhibition of β-hematin formation are separately determined. They also suggest that electron withdrawing groups at the 7-position, but not necessarily hydrophobic groups are required for hemozoin inhibition. The upshot is that the correlations imply that considerably more hydrophilic hemozoin inhibitors are feasible.

Synthesis and in vitro antitubercular activity of a series of quinoline derivatives

A series of 33 quinoline derivatives have been synthesized and evaluated for their in vitro antibacterial activity against Mycobacterium tuberculosis H37Rv using the Alamar Blue susceptibility test and the activity expressed as the minimum inhibitory concentration (MIC) in μg/mL. Compounds 5e and 5f exhibited a significant activity at 6.25 and 3.12 μg/mL, respectively, when compared with first line drugs such as ethambutol and could be a good starting point to develop new lead compounds in the fight against multi-drug resistant tuberculosis.